RSV is a leading cause of respiratory tract disease in infants and the elderly. RSV has
limited therapeutic interventions and no FDA-approved vaccine. Gaps in our understanding …

Highlights•There are multiple neutralizing antibody binding sites on F protein and at least
one on G protein.•The most potent neutralizing antibodies recognize sites exclusively on the …

Abstract Layer-by-layer (LbL) based self-assembly of nanoparticles is an emerging and
powerful method to develop multifunctional and tissue responsive nanomedicines for a …

Respiratory syncytial virus (RSV) is the principal cause of bronchiolitis in infants and a
significant healthcare problem. The RSV Glycoprotein (G) mediates attachment of the virus …

Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract disease
in young children and a substantial contributor to respiratory tract disease throughout life …

Human respiratory syncytial virus (HRSV) is a leading cause of severe acute lower
respiratory tract infection in infants and children worldwide. Bovine RSV (BRSV) is closely …

Extraordinary progress in the structure and immunobiology of the human respiratory
syncytial virus glycoproteins has been accomplished during the last few years …

Respiratory Syncytial Virus (RSV) is the major cause of pneumonia among infants. Here we
elucidated the antibody repertoire following primary RSV infection and traced its evolution …

Background: Respiratory syncytial virus (RSV) is a poor inducer of antiviral interferon (IFN)
responses which result in incomplete immunity and RSV disease. Several RSV proteins …

Respiratory syncytial virus (RSV) infection can cause bronchiolitis, pneumonia, morbidity,
and some mortality, primarily in infants and the elderly, for which no vaccine is available …